TP53 Loss Fuels mTORC1 Activation and Autophagy Suppression to Drive Immune-Cold Colorectal Cancer

TL;DR

This study shows that loss of the TP53 gene in colorectal cancer leads to immune suppression by activating mTORC1 and reducing autophagy, making the tumor 'immune-cold'.

Contribution

The paper provides protein- and phosphosite-level evidence linking TP53 loss to immune suppression in microsatellite-stable colorectal cancer.

Findings

TP53-mutant tumors show increased mTORC1 signaling and reduced autophagy across multiple datasets.

Proteomic data confirm sustained mTORC1 activity in p53-deficient tumors through phosphorylation changes.

TP53 loss is associated with FOXP3-dominant immune-cold features in colorectal cancer.

Abstract

Microsatellite-stable colorectal cancer (MSS CRC) is typically resistant to immune checkpoint blockade and remains an “immune-cold” disease. Wild-type p53 is known to restrain mTOR signaling and support autophagy, yet how TP53 loss integrates metabolic rewiring with immune suppression in MSS CRC—especially with protein- and phosphosite-level validation—remains incompletely defined. We tested whether p53 deficiency is associated with coordinated mTORC1 activation, autophagy attenuation, and immune-cold remodeling across multi-omics datasets.

We analyzed GSE146009 (paired tumor-normal RNA-seq pairs), TCGA-COAD/READ (n = 647, mutation annotated), GSE108989 (11,138 tumor-infiltrating T cells), and CPTAC colon proteome/phosphoproteome cohorts. Pathway activities were quantified by single-sample gene set enrichment analysis (ssGSEA) and Seurat module scoring. Group differences were tested by Kruskal–Wallis and Wilcoxon analyses with false-discovery-rate correction. CPTAC phosphosite-to-protein ratios were compared between TP53-mutant or p53-low versus wild-type or p53-high tumors.

Across bulk transcriptomes, TP53-mutant tumors showed higher mTORC1 signaling, lower autophagy scores, higher FOXP3, and reduced CD8A/FOXP3 ratios consistent with a regulatory T-cell-skewed immune-cold state. Single-cell analysis confirmed subset-specific immunometabolic programs, highlighting metabolically active regulatory/exhausted states with relatively blunted inflammatory output. Proteomic/phosphoproteomic data supported post-translational mTOR pathway activation in p53-deficient tumors, including increased phosphorylation of canonical mTOR substrates (EIF4EBP2 S65; RPS6KB1 T421/S424) and reduced phosphorylation at inhibitory RPTOR sites (S705/T725/S726), consistent with sustained mTORC1 activity.

In MSS CRC, p53 deficiency is consistently associated with immunometabolic remodeling marked by persistent mTOR pathway activation, relative autophagy attenuation, and FOXP3-dominant immune-cold features across transcriptomic, single-cell, and proteomic layers. These findings add protein- and phosphosite-level evidence linking TP53 loss to an immune-suppressive metabolic state and support biomarker-guided evaluation of mTOR kinase (TORC1/2) inhibition, which more fully suppresses 4E-BP/S6K phosphorylation, combined with PD-1/PD-L1 (± CTLA-4) blockade in TP53-deficient MSS CRC.

Figures